Clene Inc.CLNNEarnings & Financial Report
Clene Inc. is a clinical-stage biopharmaceutical company that develops novel neuroprotective therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson’s disease. It operates primarily in the U.S. market, focusing on advancing its small molecule candidate pipeline through clinical trials to address unmet medical needs.
CLNN Q4 FY2025 Key Financial Metrics
Revenue
$77.0K
Gross Profit
$54.0K
Operating Profit
$-7.5M
Net Profit
$-9.2M
Gross Margin
70.1%
Operating Margin
-9733.8%
Net Margin
-11981.8%
YoY Growth
-15.4%
EPS
$-0.93
Clene Inc. Q4 FY2025 Financial Summary
Clene Inc. reported revenue of $77.0K (down 15.4% YoY) for Q4 FY2025, with a net profit of $-9.2M (up 31.9% YoY) (-11981.8% margin). Cost of goods sold was $23.0K, operating expenses totaled $7.5M.
Key Financial Metrics
| Total Revenue | $77.0K |
|---|---|
| Net Profit | $-9.2M |
| Gross Margin | 70.1% |
| Operating Margin | -9733.8% |
| Report Period | Q4 FY2025 |
Clene Inc. Annual Revenue by Year
Clene Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $200.0K).
Clene Inc. Quarterly Revenue & Net Profit History
Clene Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $77.0K | -15.4% | $-9.2M | -11981.8% |
| Q3 FY2025 | $15.0K | -82.8% | $-8.8M | -58513.3% |
| Q2 FY2025 | $27.0K | -70.3% | $-7.4M | -27477.8% |
| Q1 FY2025 | $81.0K | +11.0% | $-751.0K | -927.2% |
| Q4 FY2024 | $91.0K | -46.5% | $-13.5M | -14889.0% |
| Q3 FY2024 | $87.0K | -19.4% | $-8.0M | -9179.3% |
| Q2 FY2024 | $91.0K | -66.2% | $-6.8M | -7456.0% |
| Q1 FY2024 | $73.0K | -31.8% | $-11.1M | -15178.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73000 | $91000 | $87000 | $91000 | $81000 | $27000 | $15000 | $77000 |
| YoY Growth | -31.8% | -66.2% | -19.4% | -46.5% | 11.0% | -70.3% | -82.8% | -15.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $45.1M | $40.3M | $31.6M | $27.3M | $25.3M | $22.1M | $22.3M | $18.1M |
| Liabilities | $40.8M | $40.8M | $35.7M | $36.2M | $30.3M | $30.7M | $34.7M | $35.7M |
| Equity | $4.3M | $-504000 | $-4.1M | $-8.9M | $-5.0M | $-8.6M | $-12.4M | $-17.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.1M | $-6.4M | $-3.0M | $-4.9M | $-5.0M | $-4.7M | $-4.0M | $-4.8M |